$3.3 million raised from oversubscribed SPP
Released
Released
Announcement PDF
Confidential draft
Neuren (NEU) - ASX Announcement
6 October 2021
Neuren raises $3.3 million from oversubscribed Share Purchase Plan
Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) today reported the successful completion of
its Share Purchase Plan (SPP) at $2.05 per share, which closed on Friday 1 October 2021. The SPP was
offered to give all shareholders in Australia and New Zealand the opportunity to subscribe for additional
shares at the same price as was offered to institutional and sophisticated investors in the recent
placement.
Applications received by eligible shareholders under the SPP totaled approximately $3.3 million,
compared with the targeted amount of $2 million. The Board has elected to accept the
oversubscriptions, rather than implement a scale-back procedure.
1,601,470 new fully paid ordinary shares are expected to be allotted under the SPP on Friday 8 October
2021, with trading expected to commence on a normal settlement basis on the ASX on Monday 11
October 2021.
Total gross proceeds of $23.3 million from the placement and SPP will accelerate the development and
increase the value of NNZ-2591 for four neurodevelopmental disorders, by enabling a Phase 2 clinical
trial in Prader-Willi syndrome and the foundational work for Phase 3 development across Prader-Willi,
Phelan-McDermid, Angelman and Pitt Hopkins syndromes. NNZ-2591 has Orphan Drug designation from
the US Food and Drug Administration for all four disorders and from the European Medicines Agency for
three.
Neuren CEO Jon Pilcher commented: “We are pleased with and grateful for the support of shareholders
in both the placement and the SPP. Neuren is now in a strong financial position as we approach the Rett
syndrome Phase 3 results for trofinetide and advance the development of NNZ-2591 for multiple
neurodevelopmental disorders in parallel.”
About Neuren
Neuren is developing two new drug therapies to treat multiple serious neurological disorders that
emerge in early childhood, none of which have any approved medicines.
The lead compound, trofinetide, is currently in a Phase 3 clinical trial for Rett syndrome with top-line
results expected in Q4 2021 and has completed a Phase 2 clinical trial in Fragile X syndrome. Both
programs have Fast Track designation from the US Food and Drug Administration (FDA). Neuren has
granted an exclusive licence to Acadia Pharmaceuticals Inc. for the development and commercialisation
of trofinetide in North America, while retaining all rights outside North America.
1 of 2
Confidential draft
Neuren is preparing to initiate Phase 2 trials of its second drug candidate, NNZ-2591, for each of PhelanMcDermid syndrome, Angelman syndrome and Pitt Hopkins syndrome. Neuren is also planning a Phase
2 trial in Prader-Willi syndrome.
Recognising the urgent unmet need, all six programs have been granted “orphan drug” designation in
the United States. Orphan drug designation provides incentives to encourage development of therapies
for rare and serious diseases.
Contact:
Jon Pilcher, CEO: jpilcher@neurenpharma.com; +61 438 422 271
ASX Listing Rules information
This announcement was authorised to be given to the ASX by the board of directors of Neuren
Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124
Forward-looking Statements
This announcement contains forward-looking statements that are subject to risks and uncertainties. Such
statements involve known and unknown risks and important factors that may cause the actual results, performance
or achievements of Neuren to be materially different from the statements in this announcement.
2 of 2
Share your feedback
Discover